177 related articles for article (PubMed ID: 26515754)
41. Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model.
Schmieder AH; Caruthers SD; Zhang H; Williams TA; Robertson JD; Wickline SA; Lanza GM
FASEB J; 2008 Dec; 22(12):4179-89. PubMed ID: 18697838
[TBL] [Abstract][Full Text] [Related]
42. Does imaging αvβ3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy?
Rylova SN; Barnucz E; Fani M; Braun F; Werner M; Lassmann S; Maecke HR; Weber WA
J Nucl Med; 2014 Nov; 55(11):1878-84. PubMed ID: 25278514
[TBL] [Abstract][Full Text] [Related]
43. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.
Clyburn RD; Reid P; Evans CA; Lefley DV; Holen I
Cancer Chemother Pharmacol; 2010 Apr; 65(5):969-78. PubMed ID: 19730863
[TBL] [Abstract][Full Text] [Related]
44. Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice.
Cui R; Takahashi F; Ohashi R; Gu T; Yoshioka M; Nishio K; Ohe Y; Tominaga S; Takagi Y; Sasaki S; Fukuchi Y; Takahashi K
Lung Cancer; 2007 Sep; 57(3):302-10. PubMed ID: 17482311
[TBL] [Abstract][Full Text] [Related]
45. Lipid Bilayer-Gated Mesoporous Silica Nanocarriers for Tumor-Targeted Delivery of Zoledronic Acid in Vivo.
Desai D; Zhang J; Sandholm J; Lehtimäki J; Grönroos T; Tuomela J; Rosenholm JM
Mol Pharm; 2017 Sep; 14(9):3218-3227. PubMed ID: 28737925
[TBL] [Abstract][Full Text] [Related]
46. Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits.
Smith EJ; Little DG; Briody JN; McEvoy A; Smith NC; Eisman JA; Gardiner EM
J Bone Miner Res; 2005 Oct; 20(10):1731-41. PubMed ID: 16160731
[TBL] [Abstract][Full Text] [Related]
47. Skeletal remodeling following clinically relevant radiation-induced bone damage treated with zoledronic acid.
Hui SK; Fairchild GR; Kidder LS; Sharma M; Bhattacharya M; Jackson S; Le C; Yee D
Calcif Tissue Int; 2012 Jan; 90(1):40-9. PubMed ID: 22083107
[TBL] [Abstract][Full Text] [Related]
48. One-step photo synthesis of protein-drug nanoassemblies for drug delivery.
Xie J; Cao Y; Xia M; Gao X; Qin M; Wei J; Wang W
Adv Healthc Mater; 2013 Jun; 2(6):795-9. PubMed ID: 23296632
[TBL] [Abstract][Full Text] [Related]
49. Zoledronic acid is effective against experimental malignant pleural effusion.
Stathopoulos GT; Moschos C; Loutrari H; Kollintza A; Psallidas I; Karabela S; Magkouta S; Zhou Z; Papiris SA; Roussos C; Kalomenidis I
Am J Respir Crit Care Med; 2008 Jul; 178(1):50-9. PubMed ID: 18388351
[TBL] [Abstract][Full Text] [Related]
50. Molecular imaging of tumor-infiltrating macrophages in a preclinical mouse model of breast cancer.
Sun X; Gao D; Gao L; Zhang C; Yu X; Jia B; Wang F; Liu Z
Theranostics; 2015; 5(6):597-608. PubMed ID: 25825599
[TBL] [Abstract][Full Text] [Related]
51. Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and its growth in xenografts.
Mousa SA; Yalcin M; Bharali DJ; Meng R; Tang HY; Lin HY; Davis FB; Davis PJ
Lung Cancer; 2012 Apr; 76(1):39-45. PubMed ID: 22024450
[TBL] [Abstract][Full Text] [Related]
52. The effects of zoledronic acid on neointimal hyperplasia: a rabbit carotid anastomosis model.
Güzeloğlu M; Gül M; Reel B; Yürekli I; Aykut K; Hazan E
Anadolu Kardiyol Derg; 2011 Mar; 11(2):93-100. PubMed ID: 21285021
[TBL] [Abstract][Full Text] [Related]
53. Krüppel-like factors KLF2 and 6 and Ki-67 are direct targets of zoledronic acid in MCF-7 cells.
Ebert R; Zeck S; Meissner-Weigl J; Klotz B; Rachner TD; Benad P; Klein-Hitpass L; Rudert M; Hofbauer LC; Jakob F
Bone; 2012 Mar; 50(3):723-32. PubMed ID: 22166808
[TBL] [Abstract][Full Text] [Related]
54. The self-assembling camptothecin-tocopherol prodrug: An effective approach for formulating camptothecin.
Lu J; Liu C; Wang P; Ghazwani M; Xu J; Huang Y; Ma X; Zhang P; Li S
Biomaterials; 2015 Sep; 62():176-87. PubMed ID: 26057133
[TBL] [Abstract][Full Text] [Related]
55. Zoledronic acid suppresses mineralization through direct cytotoxicity and osteoblast differentiation inhibition.
Patntirapong S; Singhatanadgit W; Chanruangvanit C; Lavanrattanakul K; Satravaha Y
J Oral Pathol Med; 2012 Oct; 41(9):713-20. PubMed ID: 22563819
[TBL] [Abstract][Full Text] [Related]
56. Activation of p38 MAPK-regulated Bcl-xL signaling increases survival against zoledronic acid-induced apoptosis in osteoclast precursors.
Tai TW; Su FC; Chen CY; Jou IM; Lin CF
Bone; 2014 Oct; 67():166-74. PubMed ID: 25016096
[TBL] [Abstract][Full Text] [Related]
57. Codelivery of zoledronic acid and doublestranded RNA from core-shell nanoparticles.
Chen L; Ding Y; Wang Y; Liu X; Babu R; Ravis W; Yan W
Int J Nanomedicine; 2013; 8():137-45. PubMed ID: 23319865
[TBL] [Abstract][Full Text] [Related]
58. Transient retention of endochondral cartilaginous matrix with bisphosphonate treatment in a long-term rabbit model of distraction osteogenesis.
Smith EJ; McEvoy A; Little DG; Baldock PA; Eisman JA; Gardiner EM
J Bone Miner Res; 2004 Oct; 19(10):1698-705. PubMed ID: 15355565
[TBL] [Abstract][Full Text] [Related]
59. Intermittent zoledronic Acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation.
Hari P; DeFor TE; Vesole DH; Bredeson CN; Burns LJ
Biol Blood Marrow Transplant; 2013 Sep; 19(9):1361-7. PubMed ID: 23806773
[TBL] [Abstract][Full Text] [Related]
60. Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages.
Tsagozis P; Eriksson F; Pisa P
Cancer Immunol Immunother; 2008 Oct; 57(10):1451-9. PubMed ID: 18297280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
